Meeting
2018 ASCO Annual Meeting
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
Authors
Julien Mazieres
Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, France
Julien Mazieres , Fabrice Barlesi , Isabelle Rouquette , Benjamin Besse , Isabelle Monnet , Clarisse Audigier-Valette , Anne Claire Toffart , Patrick-Aldo Renault , Severine Moreau Fraboulet , Sandrine Hiret , Bertrand Mennecier , Didier Debieuvre , Virginie Westeel , Philippe Masson , Anne Madroszyk , Elodie Amour , Franck Morin , Gerard Zalcman , Denis Moro-Sibilot , Pierre Jean Souquet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01556191
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9097)
DOI
10.1200/JCO.2018.36.15_suppl.9097
Abstract #
9097
Poster Bd #
420
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC.
First Author: Julien Mazières
Poster
2014 ASCO Annual Meeting
Clinical impact of gastric acid suppressing medication use on the efficacy of elrotinib and gefitinib in patients with advanced non-small cell lung cancer harboring EGFR mutations.
First Author: Yoshitaka Zenke
Poster
2012 ASCO Annual Meeting
Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
First Author: Stephanie Heon
Poster
2011 ASCO Annual Meeting
First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicentre academic phase II study in caucasian patients (pts) (NCT00339586). FIELT study group.
First Author: J. De Greve